← All indications
Preleukemia
Conditions in which the abnormalities in the peripheral blood or bone marrow represent the early manifestations of acute leukemia, but in which the changes are not of sufficient magnitude or specificity to permit a diagnosis of acute leukemia by the usual clinical criteria.
Drugs by status
Phase 2 trials (5)
Phase 1 trials (6)
Organizations
Organization Involved with Phase 4 Indications (23)
- PETHEMA Foundation
- Soochow University
- Ben Gurion University
- Cornell University
- University of Maryland
- Tel Aviv University
- Radboud University
- Astellas
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- University of Valencia
- Harbin Medical University
- Grenoble Alps University
- Novartis
- Tianjin Medical University
- University of South Florida
- Eisai
- Roche
- Celgene
- Universidad Autonoma de Barcelona
- Katholieke Universiteit Leuven
- Hebrew University
- Association pour la recherche sur les Affections Malignes en Immunologie Sanguine
- Chinese Society of Hematology
Organization Involved with Phase 3 Indications (96)
- Shanghai Ruijin Hospital North
- Shanghai institute of Hematology
- University of Michigan
- The Christie NHS Foundation Trust
- Albert Einstein Israelite Hospital
- University of Washington
- Vanderbilt University
- Sanofi
- Oregon Health and Science University
- University of Lausanne
- Cancer and Leukemia Group B (CALGB)
- St. Jude Children's Hospital
- Virginia Commonwealth University
- State University of New York, Buffalo
- National Heart, Lung, and Blood Institute (NHLBI)
- Neovii Biotech
- University of London
- Gamida Cell
- National Marrow Donor Program
- Groupe Francophone des Myelodysplasies
- Hopital Americain
- Merck
- Shanghai 6th People's Hospital
- Centocor
- Acceleron Pharma, Inc.
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Government of Canada
- University of Texas at Houston
- University of Kansas
- Katmai Oncology Group
- +66 more
Organization Involved with Phase 2 Indications (225)
- Paris Diderot University
- Ariad Pharmaceuticals
- Catholic University of Korea
- Karyopharm Therapeutics Inc
- Vion Pharmaceuticals
- Moorgreen Hospital, Southampton
- National Institutes of Health (NIH)
- University of Siena
- Targazyme, Inc.
- Shandong University
- Novacea
- Ortho Biotech, Inc.
- Institut Paoli-Calmettes
- Northside Hospital, Inc.
- Oncology Specialties, PC
- University Hospital of Mont-Godinne
- University of California, San Francisco
- Cell Therapy Transplant Canada
- Chao Family Comprehensive Cancer Center
- Wake Forest University
- TetraLogic Pharmaceuticals
- Louis A. Weiss Memorial Hospital
- Chiltern International
- Korea Research Institute of Bioscience & Biotechnology
- Bambino Gesù Hospital and Research Institute
- University of California, Davis
- University of Illinois at Chicago
- ExcellThera
- Cancer Biotherapy Research Group
- Mesoblast, Inc.
- +195 more
Organization Involved with Phase 1 Indications (81)
- Selvita S.A.
- Constant Pharmaceuticals
- HonorHealth Research Institute
- Array BioPharma
- Athersys, Inc
- CLL Global Research Foundation
- Ziopharm
- Immunomedics
- Sun Yat-Sen University
- Jasper Therapeutics, Inc.
- AIDS Malignancy Consortium
- Intrexon
- University of Copenhagen
- Celyad
- Enzon
- AstraZeneca
- Herlev Hospital
- The National Cancer Center
- CH Annecy
- Chinese Academy of Medical Sciences
- Big Ten Cancer Research Consortium
- Loxo Oncology
- Innovive Pharmaceuticals
- PersImmune, Inc
- BioTheryX, Inc.
- SymBio Pharmaceuticals
- University of Miami
- Ono Pharmaceuticals
- American Cancer Society, Inc.
- Agios Pharmaceuticals, Inc.
- +51 more
Organization Involved with Other Experimental Indications (10)